AURORA 2: Aurinia Renal Response in Lupus With Voclosporin
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Voclosporin (Primary) ; Mycophenolate mofetil; Steroids
- Indications Lupus nephritis
- Focus Adverse reactions; Registrational
- Acronyms AURORA 2
- Sponsors Aurinia Pharmaceuticals
- 15 Nov 2024 According to Aurinia Pharmaceuticals Inc. media release, company will present data from this study at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., Sunday, November 17, 2024.
- 11 Oct 2024 According to Aurinia Pharmaceuticals Inc. media release, company will present new data highlighting the important role that LUPKYNIS in Treating Lupus Nephritis will be presented at the American Society of Nephrology (ASN) Kidney Week 2024 taking place in San Diego, CA October 23-27.
- 24 Sep 2024 According to an Aurinia Pharmaceuticals media release, the company announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis (LN) based on data from the AURORA Clinical Program